Is a complete HBIO research report available?

No complete published report is available for Harvard Bioscience, Inc. (HBIO) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

Harvard Bioscience, Inc. (HBIO)

NASDAQ: HBIO · USD

$6.00

-0.12 (-2.0%)· Recorded snapshot

Coverage state: Market snapshot only — no published research

Market snapshot recorded 2026-07-31 02:00 UTC. No published research is attached to this ticker. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate the first HBIO analysis

Start the full research workflow when this ticker is ready in our data system.

Market cap	27.1M
Revenue (ttm)	85.5M
Net income (ttm)	-9.8M
EPS (ttm)	-$2.22
Shares out	4.5M
Volume	6,779
Beta	1.49
Price target	$6.00	0.0%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 85.5M
Net income (ttm): -9.8M
EPS (ttm): -$2.22
Market cap: 27.1M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	27.4B	36.9x	5.7x	96.6%	+47.5%	-37.8%	Strong Buy
ARGX	argenx SE	53.8B	31.3x	10.1x	50.6%	+58.8%	+45.7%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All HBIO indicators

Market & fundamental data

Available fields

241

Groups with data

Currency

USD

Showing 241 of 241 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001123494
Company name	Harvard Bioscience, Inc.
Country	United States
Country code	US
Cusip	416906204
Employees	339
Employees Change	-16%
Employees Change Percent	-4.51
Enterprise value	$64M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Medical Instruments & Supplies
Industry PE	68.75
Industry PE Fwd	21.7
IPO Date	2000-12-07
Isin	US4169062043
Last refreshed	2026-07-31
Market cap	$27.1M
Market cap category	Nano-Cap
Price	$6
Price currency	USD
Rev Per Employee	252,303.83x
Sector	Healthcare
Sector PE	45.21
Sector PE Fwd	23.64
Sic	3826
Symbol	HBIO
Website	https://www.harvardbioscience.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-36.28%
EV Sales Forward	0.71x
EV/EBITDA	11.52x
EV/FCF	33.51x
EV/Sales	0.75x
FCF yield	7.08%
P/B ratio	2.75x
P/S ratio	0.32x
PS Forward	0.3x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	-0.1%
EBITDA Margin	6.49%
FCF margin	2.23%
Gross margin	58.42%
Gross Profit	$50M
Gross Profit Growth	-4.31%
Gross Profit Growth Q	0.49%
Gross Profit Growth3 Y	-8.14%
Gross Profit Growth5 Y	-3.75%
Net Income	$-9.8M
Net Income Growth Quarters	1%
Net Income Growth Years	0%
Pretax Margin	-11.57%
Profit Margin	-11.44%
Profit Per Employee	$-28,861
ROA	1.73
Roa5y	-0.18
ROCE	-0.16
ROE	-78.65
Roe5y	-36.52
ROIC	4.53

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	-14.43%
Cagr15y	-11.63%
Cagr1y	20.04%
Cagr20y	-8.12%
Cagr3y	-49.9%
Cagr5y	-40.51%
EPS Growth Quarters	1
EPS Growth Years	0
FCF Growth	273.78%
FCF Growth3 Y	-19.1%
FCF Growth5 Y	-21.57%
OCF Growth	1.92%
OCF Growth10 Y	20.53%
OCF Growth3 Y	-14.62%
OCF Growth5 Y	-16.29%
Revenue Growth	-6.42x
Revenue Growth Q	-4.68x
Revenue Growth Years	0x
Revenue Growth3 Y	-9.27x
Revenue Growth5 Y	-4.08x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$1.08
Assets	$77.9M
Cash	$7.1M
Current Assets	$47.5M
Current Liabilities	$23.9M
Debt	$44.1M
Debt EBITDA	$7.94
Debt Equity	$4.39
Debt FCF	$23.1
Equity	$10M
Interest Coverage	-0.02
Liabilities	$67.9M
Long Term Assets	$30.5M
Long Term Liabilities	$44M
Net Cash	$-37M
Net Cash By Market Cap	$-137
Net Debt EBITDA	$6.67
Net Debt Equity	$3.69
Net Debt FCF	$19.38
Tangible Book Value	$-6.2M
Tangible Book Value Per Share	$-1.38
WACC	11.08

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	1.99
Inventory Turnover	1.58
Net Working Capital	$18.1M
Quick ratio	0.91
Working Capital	$23.6M
Working Capital Turnover	$13.25

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-1.91%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	-78.95%
1Y total return	20.02%
200-day SMA	5.93
3Y total return	-87.43%
50-day SMA	6.05
50-day SMA vs 200-day SMA	50over200
5Y total return	-92.55%
All Time High	145
All Time High Change	-95.86%
All Time High Date	2001-09-04
All Time Low	2.81
All Time Low Change	113.3%
All Time Low Date	2025-05-28
ATR	0.27
Beta	1.49
Beta1y	2.59
Beta2y	2.19
Ch YTD	-10.29
High	6.06
High52	9.4
High52 Date	2025-10-30
High52ch	-36.17%
Low	5.98
Low52	3.76
Low52 Date	2025-10-17
Low52ch	59.79%
Ma50ch	-0.89%
Price vs 200-day SMA	1.25%
RSI	50.09
RSI Monthly	35.05
RSI Weekly	51.08
Sharpe ratio	0.61x
Sortino ratio	1.08
Total Return	-1.91%
Tr YTD	-10.29
Tr15y	-84.35%
Tr1m	-2.04%
Tr1w	-3.07%
Tr3m	-2.12%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	2
Analyst Ratings	Hold
Earnings EPS Estimate	$-0.15
Earnings Revenue Estimate	21,450,000x
Earnings Revenue Estimate Growth	4.89x
Operating Income	$2.2M
Operating Income Growth5 Y	-15.23
Operating margin	2.55
Price target	$6
Price Target Change	$0

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	3,505,161%
Float Percent	77.72%
Net Borrowing	3,650,000
Shares Insiders	7.18%
Shares Institutions	27.78%
Shares Out	4,510,217
Shares Qo Q	0.29%
Shares Yo Y	1.91%
Short Float	1.6%
Short Ratio	3.55
Short Shares	1.24

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$398,000
Adjusted OCF	1,569,000
Average Volume	11,430.15x
Bv Per Share	2.23
CAPEX	$-1.2M
Ch10y	-78.95
Ch15y	-88.14
Ch1m	-2.04
Ch1w	-3.07
Ch1y	20.02
Ch20y	-86.08
Ch3m	-2.12
Ch3y	-87.43
Ch5y	-92.55
Ch6m	11.82
Change	-1.96%
Change From Open	-0.66
Close	6.12
Days Gap	-1.31
Depreciation Amortization	5,640,000
Dollar Volume	40,674
Earnings Date	2026-08-11
Earnings Time	bmo
EBIT	$-86,000
EBITDA	$5.6M
EPS	$-2.22
F Score	6
FCF	$1.9M
FCF EV Yield	2.98x
FCF Per Share	$0.42
Financing CF	-96,000
Fiscal Year End	December
Founded	1,901
Goodwill	9,372,000
Income Tax	$-115,000
Investing CF	-1,800,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-12
Last Report Date	2026-03-31
Last Split Date	2026-03-16
Last Split Type	Reverse
Last10k Filing Date	2026-03-13
Ma150	5.88
Ma150ch	1.99%
Ma20	6.13
Ma20ch	-2.15%
Net CF	1,552,000
Next Earnings Date	2026-08-11
Open	6.04
Optionable	Yes
P FCF Ratio	14.12
P FCF Ratio SBC	67.77
P OCF Ratio	8.75
P OCF Ratio SBC	17.19
Position In Range	25
Post Close	6
Postmarket Change Percent	1.5
Postmarket Price	$6.09
Ppne	11,599,000
Price Date	2026-07-30
Price EBITDA	$4.86
Relative Volume	0.59x
Revenue	85,531,000x
SBC By Revenue	1.77x
Share Based Comp	1,512,000
Tax By Revenue	-0.13x
Tr20y	-81.63%
Tr6m	11.82%
Us State	Massachusetts
Volume	6,779
Z Score	-2.16

Harvard Bioscience, Inc. (HBIO)

Coverage state: Market snapshot only — no published research

Generate the first HBIO analysis

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · HBIO

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All HBIO indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on HBIO

Frequently asked questions